# An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome

> **NCT01751867** · PHASE3 · COMPLETED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 135 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Decitabine at 15 mg/m2
- **DRUG:** Decitabine at 20 mg/m2

## Key facts

- **NCT ID:** NCT01751867
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-05
- **Final completion:** 2013-04
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2016-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01751867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01751867, "An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01751867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*